LATHA PADMANABHAN

** ******* *** • Lexington, MA 02420 • 781-***-**** • e6cj19@r.postjobfree.com

OBJECTIVE

A challenging position as a Biostatistician/SAS Programmer/Statistical Data Analyst to fully utilize and develop further my professional skills

SUMMARY

• SAS Programmer/Statistical Data Analyst with over ten years experience

• Effectively managed information and improved data processing procedures.

• Successfully selected appropriate statistical methodology and analyzed data

• Presented summary of clinical findings - communicated to Statisticians and non-statisticians.

• Team player with excellent communication, analytical, and problem solving skills.

WORK EXPERIENCE

Smith Hanley Consulting, Houston, TX Nov, ’08- Mar, ‘09

Client: Veristat Inc., Holliston, MA

Conducted statistical programming activities for clinical trials following established standardized design and programming procedures. Developed statistical programs to produce data sets, data documentation, data listings, tables, and integrated summaries of safety and efficacy, ad hoc analyses.

New England Research Institute, Inc., Watertown, MA

Involved in data analysis of multi-centered clinical trial of hepatitis C.

Statistician II May 2004-Feb 2008

Statistician I Jan. 2000-Apr. 2004

RESPONSIBILITIES:

Extraction of raw SAS data sets from data management system, coordinate site monitoring activities, and reporting data from sites, ascertain inconsistencies in collected data and initiate resolution of problems, merge data from different sources, generate and maintain analysis data sets, select right statistical technique to analyze data, summarize and communicate results to principal investigators.

ACCOMPLISHMENTS:

• Successfully used SAS data step to accomplish several data management tasks and creation of analysis data sets.

• Produced descriptive statistics to summarize data numerically and graphically

• Used appropriate inferential statistics to model patterns of data using t-test, chi-square tests, correlations, multivariate regressions, analysis of variance, logistic regression, Cox regression analysis, and repeated measures ANOVA.

• Participated in regular conference calls with principal investigators and Steering Committee meetings to communicate results

• Involved in different projects, which resulted in several publications.

Boston University, Boston Feb.1996- Jun. 1999

Data Coordinating Center, School of Public Health

Statistical Analyst

• Providing data management and analysis using appropriate statistical methodology and interpretation of results using SAS.

Bajaj Institute of Management, Bombay, India Jul.1987-Aug.1988

Resistant Assistant- Assisted in the research activities and teaching the course ”Introduction to computers and Pascal Programming” for the Diploma in Computer Management Students

EDUCATION

M. A. (1992) Statistics University of Rochester, NY

M. Sc. (1990) Statistics University of Alberta, Canada

Diploma (1986) Computer Programming Indian Institute of Science

M. Sc. (1984) Statistics Bangalore University, India

PUBLICATIONS

1. R. J. Fontana, Z. Kronfol, K. L. Lindsay, L. A. Bieliauskas, L. Padmanabhan, C. Back-Madruga, A. S.F. Lok, E. C. Wright, “Changes in Mood State and Biomarkers During Peginterferon and Ribavirin Treatment of Chronic Hepatitis C” American Journal of Gastroenterology. 103:2766-2775 (2008)

2. R.J. Fontana, L. A. Bieliauskas, K. L. Lindsay, C. Back-Madruga, E. C. Wright, K K. Snow, A. S.F. Lok, Z. Kronfol, L. Padmanabhan, “Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C“, Hepatology 45 (5), 1154 –1163 (2007)

3. L. A. Bieliauskas, C Back-Madruga, K. L. Lindsay, K. K. Snow, Z. Kronfol , A. S. Lok, L. Padmanabhan, and R. J. Fontana, “Clinical Relevance of Cognitive Scores in Hepatitis C Patients with Advanced Fibrosis”, J. Clinical and Neuropsychology 28 (8) 1346-1361 (2006).

4. R. J. Fontana, L. A. Bieliauskas, C. Back-Madruga, K. L. Lindsay, Z. Kronfol, A. S. Lok, L. Padmanabhan, Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C Trial”, Hepatology 43 (43), 614-622 (2005).

5. A. Lok, J. Everhart, R. Chung, L. Padmanabhan, J. Greenson, M. Shiffman, G. Everson, K. Lindsay, H. Bonkovsky, A. Di Bisceglie, “Hepatic Steatosis in Hepatitis C: Comparison of Diabetic and Nondiabetic Patients I the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial”, Clinical Gastroenterology and Hepatology, 5 (2), 245-254 (2003).

6. J. Samet, K. A. Freedberg, B. J. Savestsky, L. M. Sullivan, L. Padmanabhan, M. D. Stein, “Discontinuation from Medical Care among HIV-Infected Persons: Squandering Treatment Opportunities”, Journal Poor and Underserved, 14 (2), 244-255 (2003).

Work Contributions Acknowledged in

1. Blunted Cytopenias and Weight Loss: New Correlates of Virologic Null Response to Retreatment of Chronic Hepatitis C. Clin Gastroenterol Hepatol. 6(2), 234-41 (2008).

2. Cognitive reserve and neuropsychological functioning in patients infected with hepatitis C. Journal of the International Neuropsychological Society, 13(4):687-92 (2007).

3. Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon. New England Journal of Medicine 359(23):2429-41 (2008)

4. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology, 132(1):103-12 (2007).

5. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C Trial. Hepatology 44(6),1675-84 (2006).

6. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results in the HALT-C cohort. Hepatology 42(2),282-92 (2005).

7. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J. Hepatol. 43(3), 434-41(2005).

8. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 126(4),1015-23 (2004).

9. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 25(5), 472-92 (2004).

10. DNA polymorphisms and response to treatment in patients with chronic hepatitis C: Results from the HALT-C trial. Journal of Hepatology. 49(4): 548-556 (2008).

Contact this candidate